Overview Financials News + Filings Key Docs Charts Ownership Insiders
All All (ex-4s) 10-K 10-Q 8-K 3,4,5 Proxy Prospectus Other
Tags Quarterly results Employment agrmnt Auditor change Director comp. Appointed director
|
INVIVO THERAPEUTICS HOLDINGS CORP. (NVIV)
|
Create: Alert |
All | News | Filings
Date Filed | Type | Description |
08/09/2023 |
10-Q
| Quarterly Report for the period ended June 30, 2023 |
05/12/2023 |
10-Q
| Quarterly Report for the period ended March 31, 2023 |
04/25/2023 |
SC 13G
| Form SC 13G - Statement of acquisition of beneficial ownership by individuals: |
03/09/2023 |
8-K
| Other Events, Financial Statements and Exhibits Interactive Data |
03/01/2023 |
10-K
| Annual Report for the period ended December 31, 2022 |
02/14/2023 |
SC 13G
| ARMISTICE CAPITAL, LLC reports a 10% stake in InVivo Therapeutics Holdings Corp. |
02/13/2023 |
SC 13G/A
| Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] |
11/22/2022 |
EFFECT
| Form EFFECT - Notice of Effectiveness: |
11/21/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
11/18/2022 |
8-K
| Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements... |
11/08/2022 |
S-1
| Form S-1 - General form for registration of securities under the Securities Act of 1933: |
11/07/2022 |
S-8
| Form S-8 - Securities to be offered to employees in employee benefit plans: |
11/07/2022 |
10-Q
| Quarterly Report for the period ended September 30, 2022 |
10/14/2022 |
D
| Form D - Notice of Exempt Offering of Securities: |
10/11/2022 |
424B3
| Form 424B3 - Prospectus [Rule 424(b)(3)]: |
10/11/2022 |
8-K
| Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities, Financial Statements and Exhibits ...
Docs:
|
"PRE-FUNDED COMMON STOCK PURCHASE WARRANT InVivo Therapeutics Holdings Corp. Warrant Shares: _______ Issue Date:______, 2022 Initial Exercise Date: _______, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from InVivo Therapeutics Holdings Corp., a Nevada corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 .    &#...",
"PRE-FUNDED COMMON STOCK PURCHASE WARRANT InVivo Therapeutics Holdings Corp. Warrant Shares: _______ Issue Date:______, 2022 Initial Exercise Date: _______, 2022 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and until this Warrant is exercised in full but not thereafter, to subscribe for and purchase from InVivo Therapeutics Holdings Corp., a Nevada corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2. Section 1 .    &#...",
"PREFERRED INVESTMENT OPTION InVivo Therapeutics Holdings Corp. Preferred Investment Option Shares: ______ Issue Date: ______, 2022 Initial Exercise Date: _______, 2022 THIS PREFERRED INVESTMENT OPTION certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and on or prior to 5:00 p.m. on _____, 20__ 1 but not thereafter, to subscribe for and purchase from InVivo Therapeutics Holdings Corp., a Nevada corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Preferred Investment Option shall be equal to the Exercise Price, as defined in Section 2. Section 1 .  ...",
"PLACEMENT AGENT PREFERRED INVESTMENT OPTION InVivo Therapeutics Holdings Corp. Preferred Investment Option Shares: ______ Issue Date: October 11, 2022 Initial Exercise Date: October 11, 2022 THIS PLACEMENT AGENT PREFERRED INVESTMENT OPTION certifies that, for value received, _____________ or its assigns is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the date set forth above and on or prior to 5:00 p.m. on October 7, 2027 but not thereafter, to subscribe for and purchase from InVivo Therapeutics Holdings Corp., a Nevada corporation , up to ______ shares of Common Stock. The purchase price of one share of Common Stock under this Preferred Investment Option shall be equal to the Exercise Price, as define...",
"Re: Registration Statement on Form S-3",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of October 7, 2022, between InVivo Therapeutics Holdings Corp., a Nevada corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to an effective registration statement under the Securities Act as to the Shares and the Pre-Funded Warrants and an exemption from the registration requirements of Section 5 of the Securities Act contained in Section 4 thereof and/or Regulation D thereunder as to the Preferred Investment Options and the Warrant Amendment, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Comp...",
"SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement is dated as of October 7, 2022, between InVivo Therapeutics Holdings Corp., a Nevada corporation , and each purchaser identified on the signature pages hereto . WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4 of the Securities Act , and Rule 506 promulgated thereunder, the Company desires to issue and sell to each Purchaser, and each Purchaser, severally and not jointly, desires to purchase from the Company, securities of the Company as more fully described in this Agreement. NOW, THEREFORE, IN CONSIDERATION of the mutual covenants contained in this Agreement, and for other good and valuable consideration, the receipt and adequacy of which are hereby acknowledged, the Company...",
"REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement is made and entered into as of October 7, 2022, between InVivo Therapeutics Holdings Corp., a Nevada corporation , and each of the several purchasers signatory hereto . This Agreement is made pursuant to the Securities Purchase Agreement, dated as of the date hereof, between the Company and each Purchaser . The Company and each Purchaser hereby agree as follows: 1.              Definitions . Capitalized terms used and not otherwise defined herein that are defined in the Purchase Agreement shall have the meanings given such terms in the Purchase Agreement. As used in this Agreement, the following terms shall have the following meanings: “ Advice ” shall ha...",
"InVivo Therapeutics Announces $9 Million Registered Direct and Private Placement Offerings, Priced At-the-Market Under Nasdaq Rules CAMBRIDGE, Mass.---- InVivo Therapeutics Holdings Corp. , a research and clinical-stage biomaterials and biotechnology company with a focus on the treatment of spinal cord injuries, today announced that it has entered into a definitive agreement with a single healthcare-focused institutional investor for the sale and issuance of 523,810 shares of the Company’ s common stock , in a registered direct offering priced at-the-market under Nasdaq rules. Concurrently with the registered direct offering, the Company entered into a definitive agreement with the investor in the registered direct offering for the sale and issuance of 1,190,476 shares of common stock in a..." |
|
10/11/2022 |
424B5
| Form 424B5 - Prospectus [Rule 424(b)(5)]: |
09/13/2022 |
8-K
| Material Modifications to Rights of Security Holders, Departure of Directors or Certain Officers; Election of Directors; Appo... |
08/18/2022 |
DEF 14A
| Form DEF 14A - Other definitive proxy statements: |
08/11/2022 |
PRER14A
| Form PRER14A - Preliminary Proxy Soliciting materials: |
08/08/2022 |
10-Q
| Quarterly Report for the period ended June 30, 2022 |
07/25/2022 |
PRER14A
| Form PRER14A - Preliminary Proxy Soliciting materials: |
07/12/2022 |
8-K
| Quarterly results |
07/08/2022 |
PRE 14A
| Form PRE 14A - Other preliminary proxy statements: |
06/02/2022 |
8-K
| Quarterly results |
05/26/2022 |
8-K
| Quarterly results |
05/13/2022 |
8-K
| Quarterly results |
05/10/2022 |
10-Q
| Quarterly Report for the period ended March 31, 2022 |
04/26/2022 |
8-K
| Material Modifications to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Yea... |
04/14/2022 |
8-K
| Other Events Interactive Data |
03/07/2022 |
10-K
| Annual Report for the period ended December 31, 2021 |
02/11/2022 |
SC 13G/A
| INTRACOASTAL CAPITAL, LLC reports a 2.5% stake in InVivo Therapeutics Holdings Corp. |
02/09/2022 |
SC 13G/A
| Lind Global Macro Fund LP reports a 8.4% stake in InVivo Therapeutics Holdings Corp. |
11/29/2021 |
8-K
| Entry into a Material Definitive Agreement, Financial Statements and Exhibits Interactive Data |
|
|
|